completely understood but are thought to function by activating a gating mechanism of pain transmission when stimulating low-threshold kinesthetic and discriminative touch large-diameter afferent fibers, subsequently inhibiting nociceptive transmission along a multitude of pain pathways, 16 resulting in diminished pain perception. Peripheral nerve stimulation has proven benefit in an assembly of neuropathic pain conditions 1, 4, 26, 27 as well as other intractable pain states. 15, 21, 28 Both PNS and peripheral nerve field stimulation (PNfS) have been shown to be effective treatment modalities for conditions associated with truncal pain, intractable abdominal pain, and fibromyalgia. 3, 21, 22 Peripheral nerve stimulation has also been successfully applied toward the treatment of a variety of chronic headache etiologies, including occipital neuralgia, 20, 29 transformed migraine, 20, 24 chronic refractory migraines, 10 craniofacial neuropathic pain, 13 cervical headaches, chronic cluster headaches, 14, 17 and chronic refractory headaches. 12 Promising advantages of PNS versus DBS and SCS are less invasive lead placement, greater target accessibility through minimally invasive techniques, lower morbidity, and potentially lower costs. Although peripheral nerve stimulators are still considered experimental in many situations, numerous patients have experienced a significant amount of pain relief, increased functionality, and improved quality of life. 19 Only recently has the US Food and Drug Administration (FDA) approved PNS, and for many years practitioners had to adapt SCS technology in an off-label manner for the purpose of peripheral neuromodulation. Moreover, approval guidelines for implantation of a permanent peripheral nerve stimulator required a successful trial of neuromodulation, but insurance preapproval of such trials became increasingly difficult to obtain, mainly due to the large expense of the implanted pulse generators and the higher complication rates of PNS relative to SCS, with an increased incidence of lead migrations, fractures, and infections. 23 But technology has advanced to the point where PNS leads can feasibly be implanted at the time of trialing, without the cost of expensive implanted pulse generators. 5, 30 For these reasons, we sought to determine the feasibility of a method of trialing PNS within the office setting. The traditional method of trialing for PNS mirrors that for SCS, requiring a multiday trial of neuromodulation delivered via implanted leads. During a 1-year period in our practice, insurance regulations became more stringent, deeming much of PNS as experimental, making it very difficult to get preapproval for the traditional multiday PNS trialing in patients who would have ordinarily met the criteria 1 year earlier. Thus, these patients were scheduled for a pharmacological block of the intended peripheral target, but first a special stimulating catheter was percutaneously placed using ultrasonography guidance, and before delivery of the pharmacological anesthetic or steroid, a short trial of electrical stimulation was performed (10-60 minutes, 0.3-0.6 mA). The stimulation settings were provided by an external generator, and the degree of pain relief was recorded. Those patients receiving ≥ 50% pain relief were approved for permanent implantation of a PNS system at a later date and were followed up for an average of 3 years, as detailed in this report.
Methods
This retrospective single-institution case study was conducted under the approval of our institutional review board. The records of all patients who had undergone trialing and implantation of a PNS system for chronic refractory pain at our institution over a 1-year period (August 1, 2012-July 31, 2013) were examined. This search revealed 17 patients, 13 who had undergone a novel in-office ultrasonography-guided StimuCath screening technique (described below) and 4 who had undergone a traditional week-long screening procedure. In all cases of trialing and implantation, ultrasonography was used to guide lead placement. Visual analog scale (VAS) pain scores 8, 10 were recorded pretrial and posttrial, and if a patient experienced ≥ 50% reduction in pain, permanent PNS system implantation was indicated. Baseline characteristics of age, sex, etiology of injury, diagnosis, duration of pain prior to therapy, duration of trial, percentage pain relief during trial based on VAS scores, and type of surgery performed were recorded for the novel-trial patients (Table 1 ) and the traditional-trial patients (Table 2) .
Patients were followed up for a mean duration of 3.0 years, and the VAS for pain was used to assess pain relief in the short-term (< 6 weeks), at 1 year, and at the last follow-up. The VAS scores were collected from patient interviews and medical records. Final outcome was also characterized as good, fair, poor, or bad, according to the following definitions: good, indicating the patient was still pleased with stimulation at the last follow-up with ≥ 50% reduction in the VAS score compared with the baseline score; fair, indicating the patient was pleased with the stimulation and still used the device but experienced < 50% reduction in the VAS score; poor, indicating 0% reduction in the VAS score; and bad, indicating an explantation procedure had occurred. Reasons for explantation were noted, and the patient's free-text comments were also recorded (Table 3) .
General Description of the Technique
The Arrow StimuCath kit (Teleflex Technologies) is routinely used by pain physicians for bedside nerve block regional anesthesia (Fig. 1) . The kit comprises a wire-reinforced polyurethane catheter with an ultrasonographically visible metal coil tip designed to provide even distribution of the anesthetic as well as an electrical current for proper site identification. The proximal end of the catheter can be connected to a Snaplock catheter/syringe connector, a unit designed to allow physicians to choose electrical stimulation for confirming catheter tip location while still gaining access to the region of interest to perform a regional nerve block. The kit contains an optional hooded pin connector or J-snare connector, designed to connect the Snaplock connector to the nerve stimulator. Under ultrasonography guidance, a Hustead needle is advanced into the target position. The StimuCath catheter is then advanced into the needle until it is approximately 3-5 cm beyond the needle tip. The Hustead needle is retracted, leaving the catheter in position. The proximal end of the catheter is connected to the Snaplock connector, which is then coupled to our stimulator. Stimulation is provided by the Stimpod NMS 410 nerve stimulator (Teleflex; typically, current intensity 0.3-0.6 mA, frequency 2 Hz, pulse width 0.1 msec) with charge-balanced biphasic waveforms and applied for a period of 10-60 minutes, as tolerated by the patient (Table  1) . Stimulation parameters are adjusted within the abovementioned ranges until optimal analgesia is accomplished. The VAS pain score from a scale of 1-10 is obtained at the end of 30 minutes. Following the stimulation period, the guidewire is removed and a local anesthetic is injected. The patient is briefly monitored for adverse effects prior to discharge. If the goal of electrically induced analgesia is achieved, the patient is deemed responsive to peripheral stimulation and considered for permanent implantation. Techniques for specific nerves including anatomical targeting have been described in other reports: great auricular nerve, 7 suprascapular nerve, 9 and iliohypogastric and ilioinguinal nerves. 
Statistical Analysis
Chi-square analysis was used to determine if the proportion of good outcomes was different based on the trialing method (StimuCath vs traditional trialing). One-sided Student t-test for nonpaired samples with equal variance was used to determine if the duration of pain prior to implantation had an adverse effect (bad vs good outcome) with significance noted at p < 0.05.
Results

Patient Demographics
Trials were deemed successful in all 17 patients as pain relief was > 80% and each patient's VAS pain score showed at least 2 points of improvement. Of the 13 patients who had undergone a StimuCath trial and ultimate implantation, all experienced ≥ 50% pain relief during the trial (with an average VAS score reduction of 88%). The stimulator was implanted in the pudendal nerve in 1 patient, occipital nerve in 4 patients, lumbar plexus in 1 patient, sciatic nerve in 1 patient, iliohypogastric/ilioinguinal nerve in 2 patients, and great auricular nerve in 4 patients ( Table 1) . Of the 4 patients who had undergone the traditional outpatient trial and implantation, all experienced more than 88% pain relief (with an average VAS score reduction of 97%). Among these patients, the stimulator was implanted in the ulnar nerve in 2 patients, bilateral cluneal nerve in 1 patient, and sural/superficial peroneal nerve in 1 patient ( Table 2 ). The average duration of symptoms before surgery was 5.4 ± 3.7 years (5.9 years for the StimuCath group and 3.8 years for the traditional group, with no difference between the groups, p = 0.32).
Long-Term Therapeutic Efficacy
Of the 17 patients, 10 were still using their stimulator at the last follow-up, 8 with good relief (≥ 50% pain relief, with an average 81% reduction in the VAS score) and 2 with fair relief (< 50% relief but still using the stimulator). Among the remaining 7 patients, the stimulator had been explanted in 4 and there had been no relief in 3. Excluding the explantation patients, follow-up ranged from 14 to 46 months, with an average of 36 months. Those with good or fair relief had experienced pain before implantation for an average of 5.1 years (range 1.8-15.2 years). A longer duration of pain trended toward a poorer outcome (bad outcome 7.6 years vs good outcome 4.1 years, p = 0.03).
Comparison of Techniques
Seven (54%) of the 13 patients with the shorter trial experienced a good or fair outcome with an average 79% reduction in the VAS score at the last follow-up (34 months, range 14-42); however, all 4 of the bad outcome cases came from this group. Three (75%) of the 4 patients with the longer trial experienced a good or fair outcome at the last follow-up (41 months, range 31-46) with an average 54% reduction in the VAS score. There was no difference between the trialing methods and the proportion of favorable (good or fair) outcomes (chi-square = 0.14, p = 0.71).
Complications
Five major complications were noted, including 4 explantations, all in the StimuCath group. Although all patients in these 4 cases had excellent trials, the stimulator was explanted for loss of efficacy in 2 patients (Case 1 at 9 months and Case 2 at 17 months). The patient in Case 7 was unable to regain stimulation efficacy after lead migration despite 2 revision attempts, and he requested stimulator explantation at 2 months. The patient in Case 4 required explantation at 6 months because of infection. One additional patient suffered a lead fracture at 1 year (Case 13) requiring revision, ultimately with good relief at the 36-month follow-up. Another patient (Case 14) required additional placement of an SCS system, with fair results. The 3 patients with poor relief went on to require multiple interventional pain procedures, still with poor pain relief.
Discussion
This study demonstrates the feasibility of using a short in-office method for trialing PNS with robust long-term efficacy.
We still lack information, awareness, and commercial support when it comes to PNS. 2 With increasing clinical indications and advancements in technology, the field of PNS continues to develop. Historically, one major obstacle has been the absence of regulatory approval and insurance support for peripheral nerve neuromodulation. Furthermore, the relatively smaller proportion of patients with isolated peripheral neuropathic pain, compared with the overall chronic pain population, has relegated PNS to a lower economic priority than SCS. In turn, low volume translates into a lack of clinical knowledge and the expertise needed to drive this cycle. 25 As a result of insurance denial, PNS remains predominantly an out-of-pocket procedure. In this report, we describe a simple and relatively inexpensive method to identify favorable candidates for peripheral neuromodulation, that is, those likely to have a good or fair outcome. This method takes advantage of the routine nerve block procedure used to inject a local anesthetic or corticosteroids, recasting it as an access technique for peripheral nerve neuromodulation. In this fashion, patients can undergo a stimulation trial while helping physicians with clinical decision making and identifying favorable candidates for subsequent permanent peripheral nerve stimulator implantation surgery.
Understandably, insurance companies have been leery of providing coverage for a therapy with a notably higher complication rate than SCS. 2 Our study results were not out of line with the literature, with 4 of 17 patients requiring explantation-2 for loss of efficacy, 1 for infection, 1 for lead migration. Two other patients required further procedures: 1 for lead replacement due to fracture and 1 for the addition of a spinal cord stimulator. Nevertheless, at the 3-year follow-up, 10 of the 17 patients were still using their stimulators with good or fair benefit, with 8 of them obtaining an average of 81% reduction in VAS pain score. One patient (Case 12) who attained fair relief had experienced pain for 15.2 years and had undergone 2 open microvascular decompressions, as well as radiosurgery and balloon ablation, prior to implantation of the PNS system, subsequently requiring no further interventions at the 3-year follow-up. He reported the psychological benefit of the ability to turn his stimulator on and off, thereby allowing him to control the pain that had previously taken control of his life without warning. Even though his VAS score only reduced from 6 to 4, he appreciated the ability to intercede in his pain and resume a normal life. Several patients with good results reported sentiments similar to those of the patient in Case 11 ("life altering in a good way"), who had experienced pain for 5.6 years prior to implantation. The patient in Case 13, who had experienced 6.7 years of sciatic neuropathic pain after a perioperative nerve block, recaptured her life so effectively with stimulation that when her lead fractured at 1 year postoperatively, she presented almost as an emergency to have the lead repaired, so anxious was she not to return to her preoperative state.
When PNS works well, it can be very effective. As this study demonstrates, long-term follow-up can be humbling, with 10 of 17 patients experiencing good or fair outcomes. For these patients, however, who had been in pain for an average of 5.1 years prior to implantation, there were few other therapeutic options left. Peripheral nerve stimulation is often the last resort and, as stated earlier, can be quite effective in select populations.
The results at the long-term follow-up are consistent with those in previous studies. In a retrospective case series of 38 patients who had undergone peripheral nerve stimulator implantation for chronic pain, 61% of the patients reported ≥ 50% pain relief at 35 months postimplantation. 18 A prospective case series examined 30 patients who underwent peripheral nerve stimulator implantation for chronic regional pain syndrome with symptoms limited predominantly in the distribution of a single peripheral nerve. At a follow-up of 2-4 years, 63% of the patients reported either good or fair results. 11 At a mean follow-up of 26.6 months, Johnson and Burchiel reported that PNS of the infraorbital and supraorbital nerves afforded 70% of patients with trigeminal neuropathic pain at least 50% pain relief. 13 As noted above, all 4 of the explant cases were from the shorter trial group. While we believe that a week-long trial of stimulation is preferable when possible, if it is not practically feasible, a short trial ranging from 10 to 60 minutes may provide just as much information as a week-long trial. Seven of 13 patients in the short trial group had a good or fair outcome at the 34-month follow-up, compared with 3 of 4 patients in the week-long trial group at 41 months. Our study did not support any difference between the 2 trialing methods.
Our study has several limitations given that it is a retrospective analysis based on a limited number of patients and the subjective nature of the VAS. All patients were tested preoperatively for a period of not more than 1 hour, as limited by patient tolerance and clinical conditions. Standardizing the trial duration and perhaps extending the period of stimulation beyond 1 hour may improve selection specificity. Including more patients in the longer trial group, if feasible, would have allowed for more statistical validity. Finally, even though we were able to trial PNS using the StimuCath, the device was originally designed for catheter tip localization and not trial stimulation, with limited options for lead configuration and exploration of the stimulation parameter space.
With the newer available technologies specifically designed for PNS with a wide array of stimulation options, the reduced cost of implantation with an externalized battery, the recent FDA approval of PNS, 30 the MRI compatibility of some of the newer PNS leads, and the extensive literature spanning at least 2 decades in support of PNS, we emphatically conclude that in select patient populations, the technology of PNS should not be considered experimental by insurance companies and, at the very least, should be allowed on a compassionate-use basis.
Conclusions
Peripheral nerve stimulation is a well-established yet underutilized method for treating chronic neuropathic pain. Patient identification is of prime importance for subsequent permanent peripheral stimulator implantation. In this report, we describe an inexpensive, 1-hour outpatient technique that enables screening for PNS with the aim of improving pain control in a subset of patients with chronic neuropathic pain refractory to conventional medical therapy. Furthermore, data in this case study support PNS as an effective long-term treatment for pain relief in this subset of patients.
